CD44 and breast carcinoma: Data from over 100 breast cancer patients who underwent neoadjuvant chemotherapy with paclitaxel and epirubicin suggest that ALDH1+ cells, but not CD44+CD24− cells, contribute to resistance against chemotherapy [61].